<DOC>
	<DOC>NCT00964665</DOC>
	<brief_summary>This study will assess the efficacy of ABF656 in chronic hepatitis B characterized by HBeAg positivity. The study is designed to establish a dose response and safety relationship sufficient to allow the subsequent design and conduct of Phase 3 trials. The trial is also designed to generate the PK data in hepatitis B patients to satisfy regulatory requirements in China.</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male or female, aged 1875 years of either nonchild bearing potential or if of child bearing potential on two adequate forms of birth control Chronic HBV infection (serum HBsAg detectable for &gt; 6 months) Serum HBeAg positive with HBV DNA &gt;106copies/mL (or &gt;200,000 IU/mL) Serum ALT must be &gt; 2 x ULN but below 10 x ULN Steroid treatment or immunosuppression 3 months prior to entry. Chest Xray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease. Hb&lt; 10g/dL or, and ANC &lt; 750/mm3 or , and platelet count &lt; 75,000 mm3 . Significant chronic medical conditions other than chronic hepatitis B which in the opinion of the investigator preclude enrollment into the study. Evidence of hepatic decompensation (i.e., ChildPugh score of B or C). Seropositive for HIV, HCV, or HDV (Hepatitis Delta virus). History of hypothyroidism or current treatment for thyroid disease. Patients with treated or untreated malignancy of any organs, with the exception of localized basal cell carcinoma Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Hepatitis B,</keyword>
	<keyword>Chronic,</keyword>
	<keyword>Hepatitis B e Antigens positive</keyword>
</DOC>